661 results about "Monocyte" patented technology

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention discloses a monoluciferase-based ADCP biological activity detection method, which comprises the following steps: separating a mononuclear cell from a human peripheral blood mononuclear cell as an effector cell, phagocytizing a Raji cell transfected by Luciferase as a target cell by the mononuclear cell, acidifying and degrading the Raji cell in a phagocytic body, and degrading the Luciferase so as to attenuate a light-emitting signal, so that the ADCP biological activity is detected. The ADCP biological activity of the antibody therapeutic drug is accurately quantified by detecting the weakening of the light-emitting signal. According to the present invention, the method only needs to separate the mononuclear cells and perform Luciferase infection on the target cells, and only needs to add the luciferase substrate after the phagocytosis process, such that the luminescence value can be read by using the microplate reader, the operation process is simple, the steps are less, the time consumption is short, the high-throughput screening is achieved, and the new direction is provided for the ADCP detection.

The invention belongs to the technical field of microbiological detection, and discloses a method for realizing dual, rapid and portable detection of Listeria monocytogenes by integrating PfAgo cutting and LAMP amplification by virtue of a fluorescence and reverse fluorescence enhanced lateral flow technology, and the method is based on an Argonaute combined isothermal amplification detection technology, integrates a signal amplification system of PfAgo cutting and LAMP isothermal amplification, and realizes rapid and portable detection of Listeria monocytogenes by virtue of a fluorescence and reverse fluorescence enhanced lateral flow technology. And the reverse fluorescence lateral flow technology is combined, so that the listeria monocytogenes can be sensitively, selectively and accurately detected on site in a short time. According to the detection method based on the visual reverse fluorescence test strip, visual and reverse fluorescence mutual verification for rapid and ultra-sensitive detection and application of Listeria monocytogenes can be realized by combining visual colorimetry and a reverse fluorescence lateral flow technology, dependence on a large instrument is not needed, the cost is relatively low, the operation is simple and convenient, and the detection method can be applied to rapid and ultra-sensitive detection of Listeria monocytogenes. And portable on-site detection of the food-borne pathogenic bacteria can be realized.

This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.

According to one embodiment, an initialization agent is for initializing blood cells derived from peripheral blood. The initialization agent includes an initialization factor group for producing iPS cells by initializing a group of blood cells including mononuclear cells derived from peripheral blood, and a group of lipid nanoparticles that encapsulate the initialization factor group. The lipid nanoparticles have a component of at least or more of 40% FFT-10 and FFT-20. FFT-10 and FFT-20 are included in equal amounts.

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.

The invention discloses a gracilaria variegata low-molecular-weight polysaccharide GBP-1a, the monosaccharide is composed of 82.8% of galactose and 17.2% of glucose through structural analysis, the molecular weight of the uniform polysaccharide is 2887Da, and the polysaccharide has no toxicity to THP-1 mononuclear cells and THP-1 macrophages within a set concentration range through activity detection; and after the polysaccharide is subjected to immune training on THP-1 mononuclear cells and THP-1 macrophages, the immune response of the polysaccharide is obviously higher than that of cells which are not subjected to polysaccharide immune training, so that the training of the polysaccharide is preliminarily deduced to possibly enable the cells to generate acquired immunity similar to vaccines.

The invention discloses a biomarker for predicting the prognosis condition of sepsis and application, and belongs to the technical field of biology. The biomarkers comprise a ratio of neutrophils to lymphocytes, a ratio of platelets to lymphocytes, a ratio of monocytes to lymphocytes, a ratio of leukocytes to lymphocytes, a system inflammatory response index and a peripheral inflammatory value. According to the method, the ratio of neutrophil to lymphocyte, the ratio of platelet to lymphocyte, the ratio of mononuclear cell to lymphocyte, the ratio of leukocyte to lymphocyte, a systemic inflammatory response index and a peripheral inflammatory value are utilized to carry out accurate prognosis risk stratification on the sepsis patient, and prognosis survival risk prediction is carried out on the sepsis patient; the accuracy and timeliness of prognosis evaluation of sepsis patients are remarkably improved, a reliable guidance basis is provided for clinical decision making, and the method has important clinical application value and popularization significance.

The invention belongs to the technical field of food microorganisms, and particularly relates to an enterococcus lactis NSK220 strain, a microbial agent and application of the enterococcus lactis NSK220 strain. The invention provides the enterococcus faecium NSK220, the clearance rate of the enterococcus faecium NSK220 on DPPH is very high, the serum SOD enzyme activity can be improved by supplementing the strain NSK220 in diet, and it is indicated that the oxidation resistance of the strain NSK220 is high. Meanwhile, the enterococcus faecium NSK220 has relatively strong self-cohesion and surface hydrophobicity, which indicates that the strain has strong colonization ability and is beneficial to long-term play of probiotic functions in intestinal tracts; the strain NSK220 can also improve the feed intake and kidney function of animals, and is beneficial to the growth and body health of the animals. The enterococcus faecium NSK220 has an inhibition effect on escherichia coli, staphylococcus aureus, salmonella, pseudomonas aeruginosa and listeria monocytogenes.

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.

This invention provides a tetrahedral antibody comprising a first domain, a second domain, a third domain, a fourth, a fifth domain, and a sixth domain, wherein the first domain and the second domain are each a Fc domain of an IgG antibody, wherein the third domain and the fourth domain are each a Fab domain of an anti-CD20 antibody wherein the fifth domain and the sixth domain are each a Fab domain of an anti-CD-19 antibody. This invention also provides methods of producing the tetrahedral antibody of the invention, pharmaceutical compositions comprising the tetrahedral antibody of the invention, and methods of treating B cell cancer, inflammatory disease, and B cell disease by administering the pharmaceutical compositions of the invention.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum strain LM2 and application of the lactobacillus plantarum strain LM2. The strain has relatively high GABA (gamma-aminobutyric acid) production capacity and nitrite degradation capacity, has a bacteriostatic effect on intestinal pathogens such as staphylococcus aureus, salmonella enteritidis, listeria monocytogenes and campylobacter jejuni, has a good bacteriostatic function, also has good acid resistance and cholate resistance, and can be used for preparing a bacterial strain for treating intestinal diseases. The strain can well survive in artificial intestinal juice and artificial gastric juice; in order to increase the yield of GABA, the accelerant capable of remarkably promoting the growth of the strain LM2 is obtained by researching the accelerant, and the highest survival rate of the freeze-dried powder prepared by optimizing the accelerant and the freeze-dried powder can reach 99% or above, the nitrite degradation rate can reach 99% or above, the yield of GABA is increased to 3.0 g / L or above, and the freeze-dried powder is bacterial powder capable of being widely applied.

The invention relates to a lung cancer organoid and peripheral blood source immune cell co-culture model and a construction method thereof. Specifically, the invention provides a construction method of a macrophage and tumor organoid co-culture model for evaluating anti-tumor activity, monocytes of autologous or allogeneic peripheral blood of a patient are induced and differentiated into high-purity macrophages in vitro, and the high-purity macrophages and lung cancer tumor organoid are subjected to three-dimensional co-culture in matrigel; the model aims at highly reducing a core interaction network of tumor cells and macrophages in TME; the dynamic change of the polarization state of the macrophage is simulated and observed; the problem that an organ-like model is incomplete due to immune component deficiency or spatial positioning distortion of an existing model is effectively solved, an experimental platform closer to the physiological state is provided for tumor immune microenvironment research, and therefore development of the tumor immune treatment field is promoted.

The invention provides a primer combination of a multiple detection kit for food-borne pathogenic bacteria and the multiple detection kit. The primer combination comprises probes and primers for detecting nine food-borne pathogenic bacteria: vibrio cholerae general type, vibrio cholerae O1 type, vibrio cholerae O139 type, vibrio parahaemolyticus, salmonella, yersinia enterocolitica, campylobacter, listeria monocytogenes and enterobacter sakakaakii, and the sequence is shown as SEQ1-31; the probe and the primer pair are used for detecting nine characteristic genes, namely a shigella universal type: ipaH, a diarrheogenic Escherichia coli universal type: eltA, sta3, sta and aggR, and enterohemorrhagic Escherichia coli: stx1, stx2, escV and rfbE, and the sequences of the probe and the primer pair are shown as SEQ32-64. According to the invention, by combining a digital PCR multiple coding technology, the detection of 12 food-borne pathogenic bacteria can be realized, and the sensitivity, the specificity and the accuracy are relatively good.

The invention discloses a method for detecting the biological activity of human immunoglobulin ADCP, which is characterized in that CHO-K1 / SPIKESARS2 is taken as a target cell, THP-1 cells (human leukemia monocytes which naturally express CD32a (Fc gamma RIIa) and CD64a (Fc gamma RIIa) and stably transfect NF-kB-Luc luciferase reporter genes) modified by genetic engineering are taken as effector cells, and a fluorescence reporter gene method is adopted for detection. Based on specific target cells and effector cells, the ADCP biological activity of two different human immune globulin preparations, namely intravenous injection human immune globulin and subcutaneous injection human immune globulin, can be accurately and reliably reflected by a drawn dose-effect curve through a detection system matched with specific human immune globulin solution concentration, and the method is simple and easy to implement. Cost is low, and practical application and popularization value is achieved.

The invention provides a method for obtaining GiNK cells through novel culture medium amplification, a large number of highly purified human natural killer (NK) cells are obtained by combining IL-15 active fragments, PI3K inhibitors, key receptors targeting the surfaces of the NK cells, antibodies enhancing activation of the NK cells and various cytokines, and the GiNK cells can be used for preparing the human natural killer cells. Expansion from human peripheral blood mononuclear cells (PBMCs) can be achieved without the use of feeder cells. Through culture for 2-3 weeks, the GiNK cells can be amplified by hundreds to thousands of times, and the proliferation efficiency, functional activity and anti-tumor effect of the GiNK cells are remarkably improved. The culture medium provided by the invention not only reduces the use concentration of cell factors, but also solves the problem of function depletion of GiNK cells in in-vitro culture through the synergistic effect of various additives, and provides important technical support for clinical application of the GiNK cells.

The invention discloses a universal mononuclear / macrophage delivery system for enhancing fibrosis part drug accumulation and application, and the universal mononuclear / macrophage delivery system comprises the following steps: (1) preparation of a carrier: adding a low-oxygen response element HRE fused MMP14 plasmid into an aqueous phase solution, then preparing an RMR-LNP suspension from the aqueous phase solution and an oil phase solution by adopting a microfluidic technology, and purifying to obtain the carrier; then, DSPE-PEG2000-TriArg is added into the purified system, incubation is carried out, and RMR-L-TriArg is obtained; and (2) transfecting the mononuclear / macrophage: co-incubating the RMR-L-TriArg and the mononuclear / macrophage, and then transfecting to obtain the mononuclear / macrophage delivery system for enhancing the drug accumulation at the fibrosis part. By constructing MMP14 high-expression macrophages, delivery to the hepatic fibrosis site can be increased, accumulation of drugs is increased, and the treatment effect is enhanced.

The invention relates to the field of cell biology, and particularly relates to a preparation method of a pancreatic cancer-related antigen-loaded polypeptide, which is characterized in that factors such as GM-CSF, IL-4, IFN-gamma, TNF-alpha, IL-1beta, IL-6, PGE2, Poly I: C, R848 and the like are added to promote mononuclear cells to be activated into DC cells, pancreatic cancer PANC-1, MIA PaCa-2, BxPC-3, KP4 and SW1990HM antigens are loaded, and not only is DC cell maturation promoted, but also pancreatic cancer-related antigens are loaded. The positive rate of CD83 + CD86 of the DC cells cultured by the method is 94.16%, and the secretion amount of IL-12p70 in a cell supernatant is (645.38 + / -36.49) pg / mL. By adopting the culture method disclosed by the invention, the maturation rate of the DC cells can be improved while the DC cells are activated, so that the culture method for promoting the maturation and amplification of the DC cells loaded with the pancreatic cancer antigen is achieved.

The present application relates to the technical field of cell function detection, and particularly relates to a method for evaluating cell function of HL-60 in monocyte activation test. The method comprises the following steps: (1) preparing HL-60 cell suspension; (2) stimulating with pyrogen; (3) quantifying total protein; (4) detecting by Western blotting; and (5) evaluating cell function. The method is based on Western blotting technology, and combines statistical analysis to realize objective and quantitative determination of the core functional index of the ability of synthesizing IL-6 protein under pyrogen stimulation, can accurately identify cells with pyrogen response function defects, provides clear experimental reference for selection of HL-60 cell generations, can pre-screen qualified cells, reduces pyrogen detection deviation caused by unqualified cell function and improper generations from the source, and effectively improves the reliability and repeatability of pyrogen detection results.

The present invention relates to a ginseng peptide and a preparation method and application thereof, belonging to the field of biotechnology. The present invention provides a ginseng peptide, wherein the ginseng peptide comprises a characteristic peptide having an amino acid sequence of at least one of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG. The present invention obtains ginseng peptides by treating fermented ginseng residue, and identifies the characteristic peptides containing the amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG in the ginseng peptides by HPLC-MS / MS. The present invention confirms through experiments that ginseng peptides and fermented ginseng hydrolysates containing ginseng peptides have excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, can improve hormone-induced osteoporosis, and can be applied to products for improving osteoporosis and its related symptoms.

Compositions and methods for treating inflammation associated with Farber disease in a subject in need thereof by administering to the subject a pharmaceutical composition comprising a recombinant human acid ceramidase in a therapeutically effective amount of about 0.1 mg / kg to about 50 mg / kg to inhibit inflammation and / or to inhibit or reduce pro-inflammatory potential of neutrophils and / or monocytes in the subject.

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

A method of assessing the safety of a gene therapy vector comprising: providing a population of genetically modified cells 18 wherein the cells have been transfected with a vector; exposing the genetically edited cells to a carcinogen 20; growing the cells to produce immortal cell lines; and comparing the survival of the test cells with a control 14 to determine if the vector contributes to carcinogenicity. Also claimed is a method of testing the safety of a vector comprising: providing test cells; genetically editing the cells with a vector and exposing cells to a carcinogen or exposing the cells to a carcinogen and modifying the cells with a vector; growing the cells; and comparing the survival of the cells to a control. The cells may be used in immunotherapy. The cells may be CAR-T cells. The cells may be from peripheral blood mononuclear cells or induced pluripotent stem cells (iPSCs). The carcinogen may be ENUA. Also claimed is a method of designing a vector for use in gene therapy by harvesting nucleic acid from the test cells, characterising the modification of the test cells, redesigning the vector, and repeating the method of testing the safety of the vector.